Treatment-Resistant Depression
Cross-source consensus on Treatment-Resistant Depression from 1 sources and 6 claims.
1 sources · 6 claims
Uses
How it works
Risks & contraindications
Comparisons
Evidence quality
Highlighted claims
- Treatment-resistant depression is defined as failure to respond to at least two adequate antidepressant trials of SSRI or SNRI medications. — Neuroinflammation and Treatment-Resistant Depression
- TRD affects 20–30% of all MDD patients, representing approximately 2.8 million people in the US. — Neuroinflammation and Treatment-Resistant Depression
- Patients with TRD consistently show elevated inflammatory biomarkers. — Neuroinflammation and Treatment-Resistant Depression
- MDD carries approximately a 15% lifetime suicide risk, most often occurring during an active depressive episode. — Neuroinflammation and Treatment-Resistant Depression
- The standard model of prescribing successive antidepressants without investigating inflammatory root causes misses the mechanism driving non-response. — Neuroinflammation and Treatment-Resistant Depression
- MDD comorbidity overlaps with cardiovascular disease, diabetes, autoimmune disease, and dementia, suggesting shared upstream inflammatory root causes. — Neuroinflammation and Treatment-Resistant Depression